

Sulfamethoxazole + trimethoprim

Essential medicine status 

Section: [6. Anti-infective medicines](#) > [6.5. Antiprotozoal medicines](#) > [6.5.4. Antipneumocystosis and antitoxoplasmosis medicines](#)

EMLc

ATC codes: [J01EE01](#)

Indication	Pneumocystosis ICD11 code: 1F2G.Z
INN	Sulfamethoxazole + trimethoprim
Medicine type	Chemical agent
Antibiotic groups	A ACCESS
List type	Core
Formulations	Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule ; 80 mg + 16 mg per mL in 10 mL ampoule Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid (EMLc) Oral > Solid: 100 mg + 20 mg tablet (EMLc) ; 400 mg + 80 mg tablet (EMLc) ; 800 mg + 160 mg tablet Oral > Solid > dispersible tablet: 100 mg + 20 mg (EMLc)
EML status history	First added in 1997 (TRS 882) Changed in 2007 (TRS 950) Changed in 2011 (TRS 965) Changed in 2023 (TRS 1049)
Sex	All
Age	Also recommended for children
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more about patents . 
Wikipedia	Sulfamethoxazole + trimethoprim 
DrugBank	Sulfamethoxazole  , Trimethoprim 

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of a new strength formulation of sulfamethoxazole + trimethoprim (dispersible tablet 100 mg + 20 mg) on the EMLc.



